NASDAQ:ODTX Odyssey Therapeutics Q3 2026 Earnings Date & Estimates $20.73 -0.84 (-3.89%) As of 10:32 AM Eastern Odyssey Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 7:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call7:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Odyssey Therapeutics in Q3 2026Odyssey Therapeutics is expected to post earnings of -$1.13 per share.Consensus EstimatesConsensus EPS-$1.13Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.74Prepare for the Q3 2026 CallPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Q2 2026 Earnings ReportQ1 2026 Earnings Report Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Odyssey Therapeutics Q3 2026 Earnings FAQ When does Odyssey Therapeutics report Q3 2026 earnings? Odyssey Therapeutics (NASDAQ:ODTX) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Odyssey Therapeutics' Q3 2026 earnings call? Odyssey Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Odyssey Therapeutics? Analysts expect Odyssey Therapeutics to post earnings of -$1.13 per share for Q3 2026. Odyssey Therapeutics Earnings HeadlinesOdyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update2 hours ago | finance.yahoo.comOdyssey Therapeutics: Q3 earnings snapshot2 hours ago | msn.comDr. Ron Paul: “It’s time to prepare”The Pentagon has plans for military bases to survive a 90-day disaster. A former Defense Intelligence Agency staffer warns that the window to prepare, even with the basics, is closing. Dr. Ron Paul, 12-term former Congressman, says tech stocks are already in bear market territory while AI-driven cyberattacks grow by the day. He's teamed up with a leading financial expert to explain how he's preparing.November 4 at 1:00 AM | Stansberry Research (Ad)Odyssey Therapeutics, Inc.'s Lock-Up Period Will Expire on November 4th (NASDAQ:ODTX)October 28, 2026 | americanbankingnews.comOdyssey Therapeutics, Inc. Presents Completed Phase 2A Od-001 Induction Results Strengthening Clinical Proof of Concept At Ueg Week 2026October 21, 2026 | marketscreener.comMOdyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation TranscriptOctober 20, 2026 | seekingalpha.comSee More Odyssey Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Odyssey Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Odyssey Therapeutics and other key companies, straight to your email. Email Address About Odyssey TherapeuticsOdyssey Therapeutics (NASDAQ:ODTX) is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways. Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells. Odyssey has described a pipeline spanning immunology and oncology, although specific programs and development stages may change as its research advances. Founded in 2021, Odyssey Therapeutics is based in the United States and was established by a team with experience in biotechnology and drug discovery. Gary Glick, a biotechnology executive and entrepreneur associated with the company’s founding, has served as its chief executive officer.View Odyssey Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushMarriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?Apple's Earnings Beat Comes With a Catch for Investors Heading Into the Holidays Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
